Genomatix Expands Operations in North America
News Jun 13, 2007
Genomatix Software GmbH has announced that is has expanded its operations in the North American market by forming a subsidiary company, Genomatix Software, Inc.
The new company, which will be headquartered in Ann Arbor, MI, was officially incorporated on May 14 and will provide sales, support, and marketing for the Genomatix product for all of North America.
“Because of the difficulties of doing business from such a great distance, the North American market share has been under-represented in terms of our overall global business”, said Klaus May, Chief Business Officer of Genomatix GmbH and Chairman of the Board of Genomatix Software, Inc. “We are very excited to have a subsidiary located in the heart of that market and will look forward to seeing our North American user base grow rapidly.”
Ann Arbor is also the home of the first Genomatix Training Academy outside of Europe. “Genomatix experienced extreme demand for training and education, well beyond a standard product training. Our scientific approaches to gene regulation and our innovative ways to look at microarray data enable us to teach university-like courses, digging deep into the underlying principles of biology. Our courses are well sought after graduate students and s scientists. Many professors use our material to teach their students eukaryotic gene regulation!” Klaus May continued.
The new company will be headed by Peter Grant, Genomatix Software Inc.’s CEO, who brings a 25 year history of success in sales and business development focused on the discovery/development continuum of the pharmaceutical process.
Says Mr. Grant: “This is an incredible opportunity representing Genomatix in North America. We have an established reputation for excellent science, a global user base, and the broadest in-depth array of easy-to-use tools available in the marketplace focused on understanding eukaryote gene regulation. And the timing is perfect for capitalizing on the explosion of genomic data becoming available for analysis. We expect to grow our business here dramatically over the next 3 years and look forward to working closely with the Munich parent company to achieve our goals.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE